221P Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN
2020 ◽
Vol 12
◽
pp. 175883592097813
2013 ◽
Vol 87
(2)
◽
pp. S175